ArticleInternational journal of general medicine2026
Expression Characteristics of Soluble sCD13 in Wet Age-Related Macular Degeneration and Its Diagnostic Value and Correlation Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explored the level of soluble CD13 (sCD13) and its correlation with angiogenic factors, evaluating the predictive efficacy of sCD13 in wet age-related macular degeneration (wAMD). Methods: 200 patients were included (58 in Non AMD group, 42 in Early AMD group, and 100 in wAMD group). Detailed routine and ophthalmologic examinations were performed on all subjects, and the central retinal thickness (CRT) and ganglion cell-inner plexiform layer (GCIPL) were determined. The concentration of sCD13 was compared. The correlation of sCD13 with PDGF, hsCRP and IL-8 was analyzed. ROC curves were plotted and the diagnostic value of sCD13 was assessed by area under the curve (AUC). Results: The sCD13 concentration of patients in the wAMD group (20.41 ± 5.86 U/mL) was higher. Age, history of smoking, CRT, hsCRP and IL-8 were higher in the wAMD group, while mean GCIPL, BCVA, and PDGF were lower. sCD13 was positively correlated with hsCRP (r = 0.505) and IL-8 (r = 0.193) and negatively correlated with PDGF (r = -0.241). sCD13 had predictive efficacy in distinguishing wAMD from non AMD and early AMD, with AUC values of 0.74 and 0.61, respectively ( Conclusion: sCD13 concentration in the affected eyes of wAMD patients is abnormally elevated and associated with elevated serum hsCRP and IL-8 levels and decreased PDGF. These results suggest that elevated sCD13 may promote the development of wAMD, emphasizing the importance of early control of sCD13 levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.